Tivozanib Dosage and Administration: Standard Dosing, Cycle Schedule, and Hepatic Impairment Adjustments

　　Tivozanib is an oral vascular endothelial growth factor receptor(VEGFR)tyrosine kinase inhibitor primarily indicated for the treatment of advanced renal cell carcinoma.The drug exerts its antitumor effect by inhibiting signaling pathways involved in tumor angiogenesis.In clinical practice,tivozanib is administered in a cyclic dosing regimen designed to balance therapeutic efficacy with safety.Understanding the standard dosing protocol,cycle structure,and dose modification strategies under special circumstances is essential for optimizing treatment outcomes while minimizing adverse effect risks.

　　The standard recommended dose of tivozanib is 1.34 mg taken orally once daily,with or without food,as there is no requirement for fasting.The dosing schedule follows a 28-day cycle structure:21 consecutive days of treatment followed by a 7-day rest period,after which the next cycle begins.As long as the patient continues to meet treatment criteria—meaning there is no disease progression or unacceptable toxicity—therapy may continue on this cyclical basis indefinitely.The rationale behind the"21 days on,7 days off"design is to allow the body a recovery period,thereby reducing the cumulative toxic burden associated with continuous drug exposure.

　　During the course of treatment,if a patient experiences adverse reactions that require clinical intervention,temporary treatment interruption and/or dose reduction may be necessary.The core principle guiding dose adjustments is the patient's actual drug tolerability,rather than self-directed changes to daily dosing frequency or intervals.The purpose of temporarily withholding the drug is to allow adverse effects to resolve;once they have returned to an acceptable level,treatment may be resumed at the same or a reduced dose.All dose modifications should be made under the assessment and guidance of the treating physician,and patients should not independently alter their dose or medication schedule.

　　For patients with moderate hepatic impairment,the starting dose of tivozanib should be reduced from the standard 1.34 mg to 0.89 mg,taken orally once daily.The cycle schedule remains consistent with the standard regimen:21 consecutive days of dosing followed by a 7-day rest period,constituting a complete 28-day cycle.The basis for this dose reduction lies in the fact that impaired hepatic function may affect drug metabolism and clearance;a lower starting dose helps maintain therapeutic efficacy while reducing the safety risks associated with drug accumulation.Relevant product information materials also explicitly specify this reduced dose for patients with moderate hepatic impairment.

　　In summary,the standard administration of tivozanib is 1.34 mg once daily,taken with or without food,in a 28-day cycle comprising 21 days of active treatment followed by 7 days off.If adverse reactions requiring management occur during therapy,treatment interruption or dose reduction may be implemented based on clinical assessment.For patients with moderate hepatic impairment,the recommended starting dose is adjusted to 0.89 mg once daily,with the cycle schedule unchanged.Throughout the entire treatment course,regular follow-up monitoring and timely dose management remain critical to ensuring both medication safety and therapeutic efficacy.